Physician profile
Sol Harari
NPI 1629066741
$2,713.72
in general payments reported to CMS, 2019-2025
25 companies · $608 in 2025
The $608 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $197 · 2021: $188 · 2022: $299 · 2023: $724 · 2024: $594 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,925.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $651.56 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $325.06 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $298.77 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $223.78 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $186.44 | 2022-2024 | Quviviq |
| Astrazeneca Pharmaceuticals Lp | $174.01 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $147.85 | 2019-2023 | Trelegy Ellipta |
| Amgen INC. | $132.37 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $91.25 | 2022-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.79 | 2023-2025 | Xifaxan |
| Abbvie INC. | $52.59 | 2021-2025 | |
| Astellas Pharma US INC | $52.58 | 2024-2025 | Veozah |
| Horizon Therapeutics Plc | $38.43 | 2023 | Krystexxa |
| Merck Sharp & Dohme LLC | $30.62 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Novartis Pharmaceuticals Corporation | $27.28 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alvogen INC | $26.65 | 2023 | Teriparatide |
| Abbott Laboratories | $23.80 | 2023 | Proclaim |
| Exact Sciences Corporation | $22.60 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $22.00 | 2024 | Voquezna |
| Allergan, INC. | $19.15 | 2019 | |
| Eisai INC. | $18.67 | 2021 | |
| Xeris Pharmaceuticals, INC. | $17.55 | 2025 | Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.45 | 2022 | |
| Gilead Sciences, INC. | $16.80 | 2024 | |
| Spinal Simplicity, LLC | $16.67 | 2024 | Ha Minuteman G3-R |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sol Harari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.